Effect of thalidomide in patients with β–thalassemia major
Introduction: Thalassemia is among the common hereditary disease, caused by synthesis of defective haemoglobin, leading to ineffective erythropoiesis, chronic haemolytic anaemia and certain clinical complications. Various treatment options are available for treatment of β–thalassemia major including regular blood transfusion, iron chelation therapy and hydroxyurea. Although complications and poor survival is still major problem in these patients. So treatment with alternative drugs can be helpful in management of these patients. Methods and materials: Prospective study, conducted at a tertiary care hospital. Study included 70 known cases of transfusion dependant thalassemia major. Age, gender, haemoglobin and serum ferritin levels were analyzed before and after treatment with thalidomide. All data were collected and analyzed in SPSS 21.0. P–value of <0.05 was considered as statistically significant. Results: Among 70 patients, 46 were males and 24 were females (male to female ratio=1.9:1). Mean age of the patients was 10.31±1.24years. Before and after treatment with thalidomide, mean haemoglobin was 8.93±1.04g/dL and 10.54±1.18g/dL respectively (p=0.011). Before and after treatment, mean serum ferritin level was 3125±143.51ng/mL and 1241±135.94ng/mL (p>0.001). Conclusion: Thalidomide proved to increased haemoglobin levels and reducing ferritin levels in patients with β–thalassemia major.